AKBA
Akebia Therapeutics, Inc.
0.919$
-1.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | 3,322.2% | – | 7,543.0% | 0.3% | 3.7% | 43.4% | 100.2% | 71.8% | 7.7% | 38.1% | 39.4% | 16.7% | |
| – | – | -3,322.2% | – | -7,443.0% | 99.7% | 96.3% | 56.6% | -0.2% | 28.2% | 92.3% | 61.9% | 60.6% | 83.3% | |
| – | – | 3,627.1% | – | 7,543.0% | 129.7% | 140.1% | 96.4% | 74.0% | 69.2% | 56.8% | 32.4% | 23.5% | 26.4% | |
| – | – | 1,791.1% | – | 1,446.9% | 15.2% | 41.9% | 45.7% | 53.3% | 83.2% | 45.1% | 1.7% | 63.6% | 45.5% | |
| – | – | 5,418.2% | – | 8,989.9% | 144.9% | 182.1% | 142.1% | 127.3% | 152.4% | 119.9% | 85.7% | 92.1% | 73.3% | |
| – | – | -5,418.2% | – | -8,889.9% | -44.9% | -85.8% | -85.5% | -127.5% | -124.2% | -27.6% | -23.8% | -31.5% | 9.9% | |
| – | – | 29.4% | – | 58.7% | 1.6% | 3.0% | 11.5% | 3.0% | 9.3% | 5.4% | 3.1% | 11.4% | 10.2% | |
| – | – | -5,288.8% | – | -8,843.5% | -43.2% | -82.7% | -85.5% | -129.9% | -132.4% | -32.2% | -26.7% | -43.3% | -1.6% | |
| – | – | -29.4% | – | -58.7% | -1.6% | -13.6% | -2.0% | -11.4% | -17.8% | 4.6% | 21.4% | – | 0.7% | |
| – | – | -5,288.8% | – | -8,843.5% | -43.2% | -82.7% | -83.5% | -118.5% | -114.7% | -32.2% | -26.7% | -43.3% | -2.3% | |
| – | – | -5,411.2% | – | -8,870.6% | -42.7% | -84.6% | -73.9% | -116.1% | -106.4% | 1.0% | -4.2% | -8.6% | 9.2% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.